Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Kulkarni, Yogesh M ^a   Suarez, Vivian ^a   Klinke, David J ^a,b  

^a West Virginia University   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOLASE; PROFILIN; RAS PROTEIN; SOMATOMEDIN C RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER MODEL; CANONICAL ANALYSIS; CELL LYSATE; CELL METABOLISM; CELL MOTILITY; CONTROLLED STUDY; DATA BASE; HUMAN; HUMAN CELL; INGENUITY PATHWAY KNOWLEDGEBASE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; DRUG EFFECT; FEMALE; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PATIENT SELECTION; PEPTIDE MAPPING; PERSONALIZED MEDICINE; PHENOTYPE; PROTEIN DATABASE; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DATABASES, PROTEIN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; PEPTIDE MAPPING; PHENOTYPE; PROTEOMICS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77954333875     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-291     Document Type: Article

References (44)

1. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998, 52:261-288. 10.1023/A:1006141703224, 10066087.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182. 10.1126/science.3798106, 3798106.
3. Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast cancer are we there yet?. Am J Clin Pathol 2004, 121(suppl 3):33-49.
4. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339:1609-1618. 10.1056/NEJM199811263392207, 9828250.
5. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 2000, 18:3172-3186.
6. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992, 89(10):4285-4289. 10.1073/pnas.89.10.4285, 49066, 1350088.
7. Clarke R, Liu MC, Bouker KB, Zhiping G, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339. 10.1038/sj.onc.1206937, 14576841.
8. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003, 12:362-367. 10.1016/S0960-9776(03)00137-1, 14659106.
9. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JFR, Ellis IO, Blmaey RW. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 1994, 29:117-125. 10.1007/BF00666187, 7912565.
10. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP. Development of herceptin resistance in breast cancer cells. Cytometry A 2004, 57(2):86-93. 10.1002/cyto.a.10095, 14750129.
11. Bruggeman FJ, Snoep JL, Westerhoff HV. Control, responses and modularity of cellular regulatory networks: acontrol analysis perspective. IET Syst Biol 2008, 2(6):397-410. 10.1049/iet-syb:20070065, 19045835.
12. Kholodenko BN, Hoek JB, Westerhoff HV, Brown GC. Quantification of information transfer via cellular signal transduction pathways. FEBS Lett 1997, 414(2):430-434. 10.1016/S0014-5793(97)01018-1, 9315734.
13. Westerhoff HV, Kell DB. What BioTechnologists knew all along...?. J Theoret Biol 1996, 182:411-420.
14. Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007, 3:140. 10.1038/msb4100180, 2063581, 17940530.
15. Russell RB, Aloy P. Targeting and tinkering with interaction networks. Nat Chem Biol 2008, 4(11):666-673. 10.1038/nchembio.119, 18936751.
16. Cox J, Mann M. Is proteomics the new genomics?. Cell 2007, 130:395-398. 10.1016/j.cell.2007.07.032, 17693247.
17. Karp NA, Lilley KS. Design and Analysis Issues in Quantitative Proteomics Studies. Proteomics 2007, 7(1):42-50. 10.1002/pmic.200700683, 17893850.
18. Chich JF, David O, Villers F, Schaeffer B, Lutomski D, Huet S. Statistics for proteomics: experimental design and 2-DE differential analysis. J Chromatogr B 2007, 849:261-272.
19. Hunt SM, Thomas MR, Sebastian LT, Pedersen SK, Harcourt RL, Sloane AJ, Wilkins MR. Optimal replication and the importance of experimental design for gel-based quantitative proteomics. J Proteome Res 2005, 4(3):809-819. 10.1021/pr049758y, 15952727.
20. Karp NA, Spencer M, Lindsay H, O'Dell K, Lilley KS. Impact of replicate types on proteomic expression analysis. J Proteome Res 2005, 4(5):1867-1871. 10.1021/pr050084g, 16212444.
21. Hondermarck H. Breast cancer: when proteomics challenges biological complexity. Mol Cell Proteomics 2003, 2:281-291.
22. Craven R, Banks R. Laser campture microdissection and proteomics: Possibilities and limitation. Proteomics 2001, 1:1200-1204. 10.1002/1615-9861(200110)1:10<1200::AID-PROT1200>3.0.CO;2-Q, 11721632.
23. Shin KH, Ku JL, Kim WH, Lee SE, Lee C, Kim SW, Park JG. Establishment and characterization of seven human renal cell carcinoma cell lines. Br J Urol Int 2000, 85(1):130-138.
24. Wistuba II, Behrens C, Milchgrub S, Syed S, Ahmadian M, Virmani AK, Kurvari V, Cunningham TH, Ashfaq R, Minna JD, Gazdar AF. Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin Cancer Res 1998, 4:2931-2938.
25. Wistuba II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, Minna JD, Gazdar AF. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res 1999, 5:991-1000.
26. Henkin JA, Jennings ME, Matthews DE, Vigoreaux JO. Mass Processing - An Improved Technique for Protein Identification with Mass Spectrometry Data. J Biomol Tech 2004, 4:230-237.
27. Klinke DJ. An empirical Bayesian approach for model-based inference of cellular signaling networks. BMC Bioinformatics 2009, 10(1):371. 10.1186/1471-2105-10-371, 2781012, 19900289.
28. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci 1992, 7:457-511.
29. Harry JL, Wilkins MR, Herbert BR, Packer NH, Gooley AA, Williams KL. Proteomics: Capacity versus utility. Electrophoresis 2000, 21:1071-1081. 10.1002/(SICI)1522-2683(20000401)21:6<1071::AID-ELPS1071>3.0.CO;2-M, 10786881.
30. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995, 57(1):125-133.
31. Pezzino V, Papa V, Milazzo G, Gliozzo B, Russo P, Scalia PL. Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann N Y Acad Sci 1996, 784:189-201. 10.1111/j.1749-6632.1996.tb16236.x, 8651569.
32. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993, 53(16):3736-3740.
33. Peyrat JP, Bonneterre J. Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat 1992, 22:59-67. 10.1007/BF01833334, 1421425.
34. Resnik JL, Reichart DB, Huey K, Webster N, Seely BL. Elevated Insulin-like Growth Factor I Receptor Autophosphorylation and Kinase Activity in Human Breast Cancer. Cancer Res 1998, 58:1159-1164.
35. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. Breast Cancer Res Treat 2000, 62(1):51-62. 10.1023/A:1006491619920, 10989985.
36. Molloy MP, Herbert BR, Williams KL, Gooley AA. Extraction of Escherichia coli proteins with organic solvents prior to two-dimensional electrophoresis. Electrophoresis 1999, 20:701-704. 10.1002/(SICI)1522-2683(19990101)20:4/5<701::AID-ELPS701>3.0.CO;2-5, 10344235.
37. Duncan MW, Hunscuker SW. Comments on standards in proteomics and the concept of fitness-for-purpose. Proteomics 2006, 6(Suppl.1-2 (Practical Proteomics)):45-47. 10.1002/pmic.200600559, 17031796.
38. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
39. Weitzel LB, Byers T, Allen J, Finlayson C, Helmke SM, Hokanson JE, Hunsucker SW, Murphy JR, Newell K, Queensland KM, Singh M, Wischmeyer PE, Duncan MW, Elias A. Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. Breast Cancer Res Treat 2010,
40. Lasfargues EY, Coutinho WG, Redfield ES. Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst 1978, 61(4):961-978.
41. Trempe GL. Human breast cancer in culture. Recent Results Cancer Res 1976, 57:33-41.
42. Karey KP, Sirbasku DA. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res 1998, 48:4083-4092.
43. Ciampolillo A, De Tullio C, Giorgino F. The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer. Curr Med Chem 2005, 12:2881-2891. 10.2174/092986705774454715, 16305477.
44. Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001, 61:589-593.